Research programme: estrogen antagonists - Chugai PharamaceuticalAlternative Names: Antiestrogen therapies research programme - Chugai Pharmaceutical; Estrogen antagonists research programme -Chugai Pharmaceutical
Latest Information Update: 16 Jul 2016
At a glance
- Originator Chugai Pharmaceutical
- Class Chromans
- Mechanism of Action Estrogen receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Breast-cancer in Japan (PO)
- 31 Mar 2005 Preclinical trials in Breast cancer in Japan (PO)